AQST Aquestive Therapeutics Inc.

3.34
+0.16  (+5%)
Previous Close 3.18
Open 3.16
Price To Book -3.41
Market Cap 83,642,287
Shares 25,042,601
Volume 42,353
Short Ratio
Av. Daily Volume 93,493
Stock charts supplied by TradingView

NewsSee all news

  1. Aquestive Therapeutics to Attend Two Upcoming Investor Conferences

    WARREN, N.J., Aug. 26, 2019 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST), a specialty pharmaceutical company focused on developing and commercializing differentiated products that meet patients' unmet

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

NDA filing due by the end of 2019.
KP415
ADHD
PDUFA date November 30, 2019.
Exservan (riluzole) Oral Film
Amyotrophic Lateral Sclerosis
Tentative approval issued August 31, 2018. Full approval issued November 2, 2018.
Sympazan
Lennox-Gastaut Syndrome
Rolling NDA filing to be completed 4Q 2019.
Libervant - AQST-203
Epileptic seizures
CRL issued November 16, 2018.
AQST-119
Erectile dysfunction
CRL issued January 30, 2019 through partner Sunovion (private company). NDA to be refiled 2H 2019.
APL-130277
Parkinson’s Disease with motor fluctuations
Phase 1 trial has been completed - September 30, 2019 - well tolerated.
AQST-108
Anaphylaxis

Latest News

  1. Aquestive Therapeutics to Attend Two Upcoming Investor Conferences

    WARREN, N.J., Aug. 26, 2019 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST), a specialty pharmaceutical company focused on developing and commercializing differentiated products that meet patients' unmet